Table 1 Clinical characteristics of converted OMG and pure OMG
From: Thymectomy in ocular myasthenia gravis—prognosis and risk factors analysis
Overall(58) | Converted OMG (13) | Pure OMG (45) | p value | |
|---|---|---|---|---|
Gender, n (%) | 0.300 | |||
Male | 24 (41.4%) | 7 (53.8%) | 17 (37.8%) | |
Female | 34 (58.6%) | 6 (46.2%) | 29 (62.2%) | |
Onset age (years), mean ± SD | 55.1 ± 13.2 | 56.3 ± 10.6 | 54.4 ± 14.1 | 0.646 |
Ptosis, n (%) | 0.448b | |||
Left | 19 (32.8%) | 4 (30.8%) | 15 (33.3%) | |
Right | 16 (27.6%) | 2 (15.4%) | 14 (31.1%) | |
Bilateral | 23 (39.7%) | 7 (53.8%) | 17 (35.6%) | |
Diplopia ( +), n (%) | 25 (43.1%) | 7 (53.8%) | 18 (40.0%) | 0.375 |
Anti-AchR Ab ( +), n (%) | 40 (69.0%) | 12 (92.3%) | 28 (62.2%) | 0.085 |
RNS ( +), n (%) | 27 (46.6%) | 11 (84.6%) | 16 (35.6%) | 0.002* |
Disease duration before surgery (weeks), mean ± SD | 19.3 ± 44.4 | 15.0 ± 27.1 | 20.5 ± 48.5 | 0.699 |
Surgical approach, n (%) | 0.562b | |||
R/L-VATS | 22 (37.9%) | 4 (30.8%) | 18 (40.0%) | |
TS | 8 (13.8%) | 3 (23.1%) | 5 (11.1%) | |
Sub-xiphoid | 28 (48.3%) | 6 (46.2%) | 22 (48.9%) | |
Tumor location, n (%) | 0.624b | |||
Left | 23 (52.3%) | 7 (58.3%) | 16 (50.0%) | |
Right | 19 (43.2%) | 4 (33.3%) | 15 (46.9%) | |
L + Ra | 2 (4.5%) | 1 (8.3%) | 1 (3.1%) | |
Maximum diameter (cm), mean ± SD | 3.8 ± 1.6 | 3.5 ± 1.3 | 3.9 ± 1.7 | 0.441 |
Mean size (cm), mean ± SD | 3.1 ± 1.2 | 2.8 ± 1.0 | 3.2 ± 1.3 | 0.351 |
Thymoma histotype + hyperplasia, n (%) | 0.137b | |||
Thymoma | ||||
AB | 10 (17.2%) | 1 (7.7%) | 9 (20.0%) | |
B1 | 4 (6.9%) | 0 | 4 (8.9%) | |
B2 | 20 (34.5%) | 7 (53.8%) | 13 (28.9%) | |
B3 | 10 (17.2%) | 4 (30.8%) | 6 (13.3%) | |
Hyperplasia | 14 (24.1%) | 1 (7.7%) | 13 (28.9%) | |
Thymoma: Hyperplasia | 44:14 | 12:1 | 32:13 | 0.228 |
B2 + B3: AB + B1 + hyperplasia | 30:28 | 11:2 | 19:26 | 0.007* |
Thymoma Stage + hyperplasia, n (%) | 0.095b | |||
Thymoma | ||||
I | 11 (19.0%) | 4 (30.8%) | 7 (15.6%) | |
IIa | 12 (20.7%) | 1 (7.7%) | 11 (24.4%) | |
IIb | 13 (22.4%) | 3 (23.1%) | 10 (22.2%) | |
III | 8 (13.8%) | 4 (30.8%) | 4 (8.9%) | |
Hyperplasia | 14 (24.1%) | 1 (7.7%) | 13 (28.9%) | |
NTOMG, n (%) | 1.000b | |||
Early-onset (age ≤ 50) | 7 (12.1%) | 0 | 7 (15.6%) | |
Late-onset (age > 50) | 7 (12.1%) | 1 (7.7%) | 6 (13.3%) | |
Post-operative prednisone ( +), n (%) | 20 (34.5%) | 4 (30.8%) | 16 (35.6%) | 1.000 |
Post-operative follow-up duration (months), mean ± SD | 59.3 ± 30.3 | 55.5 ± 36.3 | 60.5 ± 28.8 | 0.608 |